VivoSim Labs, Inc.
LSE: 0R02.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Keith E. Murphy
- Employees
- 14
- Headquarters
- Solana Beach, United States
- IPO year
- 2014
- Market cap
- $3.7M
- Website
- https://vivosim.ai
Loading 0R02…
Loading profile data…Frequently asked questions about 0R02
What does VivoSim Labs, Inc. (0R02.L) do?
VivoSim Labs, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing...
Where does 0R02.L trade?
VivoSim Labs, Inc. (0R02.L) trades on the London Stock Exchange.
What sector is 0R02.L in?
VivoSim Labs, Inc. (0R02.L) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of VivoSim Labs, Inc.?
Keith E. Murphy is the chief executive officer of VivoSim Labs, Inc. (0R02.L).
Where is VivoSim Labs, Inc. headquartered?
VivoSim Labs, Inc. is headquartered in United States.
Does 0R02.L pay a dividend?
VivoSim Labs, Inc. (0R02.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0R02.L go public?
VivoSim Labs, Inc. (0R02.L) completed its initial public offering in 2014.